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Edited by Veli-Pekka LehtoAbstract Hepatocellular carcinoma (HCC) is the most com-
mon primary cancer of the liver. Thus there is great interest to
identify novel HCC diagnostic markers for early detection of
the disease and tumour speciﬁc associated proteins as potential
therapeutic targets in the treatment of HCC. Currently, we
are screening for early biomarkers as well as studying the devel-
opment of HCC by identifying the diﬀerentially expressed pro-
teins of HCC tissues during diﬀerent stages of disease
progression. We have isolated, by reverse transcriptase and poly-
merase chain reaction (RT-PCR), a 1741 bp cDNA encoding a
protein that is diﬀerentially expressed in HCC. This novel
protein was initially identiﬁed by proteome analysis and we
designate it as Hcc-2. The protein is upregulated in poorly-
diﬀerentiated HCC but unchanged in well-diﬀerentiated HCC.
The full-length transcript encodes a protein of 363 amino acids
that has three thioredoxin (Trx) (CGHC) domains and an ER
retention signal motif (KDEL). Fluorescence GFP tagging to
this protein conﬁrmed that it is localized predominantly to the
cytoplasm when expressed in mammalian cells. Protein align-
ment analysis shows that it is a variant of the TXNDC5 gene,
and the human variants found in Genbank all show close similar-
ity in protein sequence. Functionally, it exhibits the anticipated
reductase activity in the insulin disulﬁde reduction assay, but
its other biological role in cell function remains to be elucidated.
This work demonstrates that an integrated proteomics and
genomics approach can be a very powerful means of discovering
potential diagnostic and therapeutic protein targets for cancer
therapy.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatocellular carcinoma (HCC or hepatoma) is the most
common primary cancer of the liver which is responsible for
approximately one million deaths each year [1]. Persistent viral
infection by the hepatitis B or C virus (HBV or HCV) is prob-
ably the most important cause of HCC worldwide which con-
tributes to about 80% of HCCs in humans [2].
HCC has a high incidence rate in the underdeveloped and
developing countries where the patients are often diagnosed
with inﬁltrative or massive tumours [3]. The incidence of
HCC is also increasing in the developed countries [4]. How-
ever, in these countries, HCC is mostly diagnosed at an asymp-
tomatic stage by routine ultrasonography since the patient’s
underlying liver disease has been detected and monitored [3].
For most patients suﬀering from HCC, long-term survival is
rare. The options for treatment are surgery, systematic chemo-
therapy, loco-regional treatment, and symptomatic relief, and
of these, only surgery has the potential to cure. Unfortunately,
liver resection is only feasible for 10–15% of the patients as
they are often presented late. Thus, there is great interest to
identify novel HCC diagnostic markers for early detection of
the disease, and tumour speciﬁc associated proteins as poten-
tial therapeutic targets in the treatment of HCC.
We are currently screening for early biomarkers of HCC as
well as studying the development of HCC by identifying the
diﬀerentially expressed proteins of HCC tissues during diﬀer-
ent stages of disease progression. In this paper, we report the
discovery of a protein, named Hcc-2, which was found to be
upregulated in poorly-diﬀerentiated HCC but not in the well-
diﬀerentiated HCC. The identiﬁcation and characterization
of Hcc-2 was performed based on an integrated proteomics,
bioinformatics and genomics approach that was described ear-
lier by us for the discovery of Hcc-1 [5].2. Materials and methods
2.1. Tissue samples
The details of the tissue samples used have been described elsewhere
[6]. Brieﬂy, we used hepatitis B virus (HBV)-infected HCC samples and
selected matched sample pairs (normal versus tumor) from the same
liver for protein expression analyses. Two types of liver tissues were
used, those that are derived from well-diﬀerentiated and poorly-diﬀer-
entiated HCC. For gene cloning of Hcc-2, total RNA was prepared
from poorly-diﬀerentiated HCC tissues.blished by Elsevier B.V. All rights reserved.
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The detailed procedure for proteome analysis by two-dimensional
gel electrophoresis (2DE) and matrix-assisted laser desorption-time
of ﬂight (MALDI-TOF) MS has previously been published [7]. Se-
lected peptide fragments were subjected to de novo sequencing on a
QSTAR tandem hybrid quadrupole-TOF (QqTOF) MS system
(MDS SCIEX, Ont., Canada) equipped with a nano-electrospray
(nESI) ionization source (MDS Protana, Odense, Denmark). Details
of the assembly method can be found in Choong et al. [5]. An addi-
tional step was introduced to validate the assembled sequence by using
two random peptide sequences from the 5 0 and 3 0 ends of the assem-
bled putative protein sequence to re-assemble and conﬁrm that there
was no more extension to the assembled sequence.
2.3. Functional and structural prediction for novel proteins
Various bioinformatics tools that are available from the internet
were used to predict the putative structure and function of the novel
proteins [5]. Besides that, PsiPred [8], Interpro [9] and GeneMine/
LOOK [10] were also adopted in predicting secondary structure, pro-
tein domain and homology modeling.
2.4. Cloning and sequencing of Hcc-2
Initial cloning of Hcc-2 was performed using degenerate primers tar-
geting 21 bp of the 5 0 and 3 0 ends. These primers were designed based
on the deduced sequence of Hcc-2 as derived from the amino acid se-
quence assembly described in Section 2.2. Total RNA was prepared
using Trizol reagent (Invitrogen, Carlsbad, CA) as per manufacturer’s
instructions. First strand cDNA was prepared by reverse transcription
on total RNA isolated from tissue samples of poorly-diﬀerentiated
HCC using an RT-PCR kit (Qiagen, Hilden). Polymerase chain reac-
tion (PCR) was carried out on a PTC-100 Peltier Thermal Cycler
(MJ Research). Each 50 ll reaction comprises 3 ll of cDNA (1 ng/
ll), high ﬁdelity polymerase, Bioxact (Bioline, UK) and primers at a
concentration of 50 nM. Cycling parameters were 95 C for 5 min fol-
lowed by 35 cycles of 95 C for 15 s, 60 C for 1 min and 72 C for
1 min. The RT-PCR product was cloned into pCR2.1–TOPO (Invit-
rogen) to give pTOPO-170-138. Upstream (5 0UTR) untranslated se-
quences of Hcc-2 were determined by random ampliﬁcation of
cDNA ends (RACE) using SMART RACE kit from Clontech (Clon-
tech, Palo Alto, CA). Reactions were performed as recommended by
manufacturer. Predicted Hcc-2 sequence was conﬁrmed by sequencing
of numerous positive clones. Upon sequencing and conﬁrmation of the
cloned Hcc-2, the coding sequence of Hcc-2 was ampliﬁed using the
primers:
Hcc-2 F 5 0GGCGCAGGCCTGCCCATATGTTCACGCACGGG-
ATCCAGAGCGCCHcc-2 R 5 0GGCCGAGATCTCCCGGGCTAA-
AGTTCGTCTTTCGCTTGGCTCAG and in addition, a StuI and
NdeI restriction site (underlined in Hcc-2 F) at the start codon (bold)
and a SmaI and BglII restriction site (underlined in Hcc-2R) after
the stop codon was introduced. The PCR product was cloned into
pCR2.1–TOPO to give pTOPO-170-138NB.
2.5. Construction of vectors for baculovirus expression of recombinant
Hcc-2
A recombinant baculovirus transfer vector was constructed using the
Bac-to-Bac system (Life Technologies). The entire open reading frame
was excised from pTOPO-170-138NB with StuI and XbaI and ligated
in frame into pFastbac HTB (Invitrogen) in StuI/XbaI sites to gener-
ate pFastbac-170. The plasmid contained a His-tag at the N-terminus
of Hcc-2. This plasmid was then used for transposition in DH10Bac
E. coli cells. After selection for transposition, the bacmid was isolated
and transfected into Sf9 cells using Cellfectin transfection reagent
(Invitrogen), and the virus was isolated. All plasmids and bacmids
were veriﬁed by DNA sequencing.
2.6. Expression and puriﬁcation of Hcc-2 in Sf9
A shake ﬂask culture of Sf9 insect cells in 500 ml of Grace’s media
supplemented with 10% fetal bovine serum and 1% pluronic was
seeded at a density of 1 · 106/ml and then infected with the virus car-
rying Hcc-2. Cells were harvested 72 h after infection, and the cell pel-
let was resuspended in 5 ml of homogenization/binding buﬀer (20 mM
Tris–HCl, pH 8.0, 5 mM imidazole, 0.5 M NaCl, Complete protease
inhibitors without EDTA, Roche Molecular Biochemicals) and themixture was incubated on ice for 30 min. Hcc-2 was then batch puriﬁed
using Talon cobalt resin (Clontech) according to manufacturer’s pro-
tocols. Puriﬁed protein was analysed on SDS–polyacrylamide gel, blot-
ted onto PVDF membrane and subjected to Edman N-terminal
sequencing on an ABI Procise 494 Protein Sequencer.
2.7. Insulin disulﬁde reduction assay
Puriﬁed Hcc-2 was tested for reductase activity using an insulin
disulﬁde reducing assay [11]. A 5 ll reaction mixture contained
100 mM potassium phosphate, pH 7.0, 0.2 mM EDTA, 1 mg insulin,
1 lg Hcc-2 or recombinant E. coli thioredoxin (TRX) (Promega, Mad-
ison, WI). The reaction was initiated by addition of 0.33 mM dithio-
threitol (DTT). Reactions proceeded at room temperature (22 C)
and were followed by measuring A595 on a Genequant spectrophotom-
eter (Amersham Biosciences, Piscataway, NJ).2.8. Construction and expression of GFP-tagged Hcc-2 in Chinese
hamster ovary (CHO) cells
A BamHI/EcoRI fragment was obtained from plasmid pTOPO-170-
138NB and ligated in frame into pEGFP-C2 (Clontech) in the BglII/
EcoRI site to generate construct, pEGFP-170, which contained a
GFP at the N-terminus of Hcc-2. To establish stably transfected cell
lines, CHO-K1 cells were transfected with plasmid pEGFP-170 using
FuGENE 6 reagent (Roche Molecular Biochemicals). As a control,
cells were also transfected with pEGFP-C2. After 24 h, cells were tryp-
sinized and plated with diﬀerent dilutions on 6-wells plates. After 10
days in selection medium containing 800 lg/ml neomycin G418 (Invit-
rogen), resulting colonies were maintained in 400 lg/ml neomycin for
further analysis.
2.8.1. Transfection of CHO cells. CHO-K1 cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) medium supplemented
with 10% FBS and incubated at 37 C with 5% CO2. Transfection was
done on 2 · 106 cells in 100 ll of Cell Line Nucleofector Solution T
(Amaxa Biosystems) with 2 lg of pEFGP-170 or pEGFP-C2 plasmid
DNA. The cell suspension was transferred into an Amaxa certiﬁed
cuvette and cells were electroporated using cell type speciﬁc nucleofec-
tor program H14 (Amaxa manual). Cells were transferred into 6-wells
plate containing 3 ml of pre-warm DMEM with 10% FBS medium.
After 24 h of recovery, cells were transferred into selective medium
(DMEM supplemented with 10% FBS and 800 lg/ml of G418 (Sig-
ma)). After 3 weeks of selection, transfected cells were adapted to ser-
um free HyQ PF-CHO MPS medium (Gibco) with 800 lg/ml of G418.
2.8.2. Microscopy. CHO-K1 cells transfected with pEGFP-170 fu-
sion protein were seeded onto 6 well culture plates (Nunc Inc., Roches-
ter, NY). At 24 h posttransfection, cells were washed twice with
phosphate buﬀered saline and images were acquired with an Olympus
IX70 inverted microscope. GFP was excited with a 450-nm laser, and a
515–565-nm bandpass ﬁlter was used for detection of the emission
ﬂuorescence. Multiple cells were inspected randomly, and only repre-
sentative ﬁelds were presented in the ﬁgures.2.9. Quantitative real time PCR and RT-PCR analysis
Human multiple tissue cDNA panels (Clontech, Catalog number
636742, 636743) containing ﬁrst-strand cDNAs from 12 human tissues:
heart, brain, placenta, lung, liver, skeletal muscle, kidney pancreas
(636742) and spleen, thymus, prostate, testis, ovary, small intestine, co-
lon, peripheral blood leukocyte (636743) were subjected to analysis
using quantitative real-time PCR (qRTPCR) on an ABI Prism 7000
Sequence Detector System (Applied Biosystems, Foster City, CA).
Each 25 ll qRTPCR reaction comprises 3 ll of cDNA (1 ng/ll), 2·
ITAQ SYBR I Master Mix (Biorad) and gene-speciﬁc primers at a con-
centration of 50 nM. Primers for Hcc-2 (AJ440721) and Homo sapiens
b-actin (Actb) mRNA (NM_001101) were used.
ACTB_F 5 0-AGAGATGGCCACGGCTGCTT-3 0
ACTB_R 5 0-ATTTGCGGTGGACGATGGAG-30
Hcc-2_F 5 0-AGGCCAAGAAGCTGTGAAGT-3 0
Hcc-2_R 5 0-TCATACAGCCCTTGCTTGAG-3 0
All reactions were performed in triplicate. Cycling parameters were
95 C for 15 min followed by 40 cycles of 95 C for 15 s and 60 C for
1 min. Transcript level of Hcc-2 in diﬀerent tissues was normalised to
actin and expressed as DCT, where DCT = CT(Hcc-2)  CT (Actin).
Relative transcript level (RTL) is obtained as RTL ¼
1000 2ðDCtÞ. RT-PCR analysis of transcript levels was performed
2218 P.M. Nissom et al. / FEBS Letters 580 (2006) 2216–2226on ﬁrst strand cDNAs generated from normal human liver and HCC
tissues. Primers 170-A, 5 0-GTGCCCCCGAGCTCAAGCAA-3 0 and
170 R, 5 0-CTAAAGTTCGTCTTTCGCTTGGCTCAG-3 0, were used
to generate a 751 bp product from Hcc-2. PCR reactions were per-
formed as described in Section 2.4, over 30 cycles.3. Results
3.1. Proteome analysis and in silico protein assembly
Fig. 1 showed a preparative 2DE map of HCC tumour tissue
with Hcc-2 (pI of 5.2 and a relative molecular mass of 55 kDa)
indicated by an arrow, while the gel insert showed that it was
upregulated in poorly-diﬀerentiated HCC tissue. As this
protein spot was not identiﬁed from the Swiss-Prot or NCBI
databases based on its peptide mass ﬁngerprinting from MAL-Fig. 1. Preparative 2DE map of poorly diﬀerentiated HCC tumour tissue.
isoelectric points and molecular weights are listed in the table as an insert. T
tumorous; and (ii) tumorous region of the liver.DI-TOF data, ﬁve of its tryptic peptides were subjected to de
novo sequencing (Fig. 2). The amino acid sequences from
the fragments were then used to search the EST database by
using BLAST (tblastn) [12]. A total of 41 ESTs were found
and this was assembled using the CAP3 [13] assembly software
into a putative in silico open reading frame (ORF). The assem-
bled ORF was conﬁrmed by carrying out a theoretical tryptic
digestion of the protein. Six peptides matching the rest of the
signiﬁcant peaks of the original peptide mass ﬁngerprints of
the protein were found (Fig. 2).
3.2. Functional and structural prediction
Using PSI-BLAST [12] on non-redundant database, Hcc-2
has 38% identity match with protein disulﬁde isomerase pre-
cursor. A search on Interpro [9] revealed that Hcc-2 has threeThe novel Hcc-2 protein is circled, and its observed and theoretical
he gel inset represents the expression proﬁle of Hcc-2 in the: (i) non-
Fig. 2. MALDI spectrum and amino acid sequence (inset) of Hcc-2. The four peptides indicated by blue asterisks were subjected to de novo
sequencing. The sequences of the peptides are boxed and in blue (inset), and one additional peptide in blue and underlined (inset), were utilised in the
in silico assembly of the protein. The peptides indicated by green asterisks were the six additional peptides with masses that matched the underlined
and green-coloured sequences (inset) of the assembled sequence.
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location of the domains. The protein was predicted by PSORT
[14] to be in the cytoplasm and it was found to have an endo-
plasmic reticulum retention motif (KDEL) in the C-terminus.
The protein was found to have no predicted transmembrane
segment (PredictProtein) [15] and no secretory signal (SignalP)
[16]. Each of the three Trx-like domains of Hcc-2 was found to
have a 40% identity match with the a domain of protein disul-
ﬁde isomerase, PDI [17] but not the b domain [18]. The a do-
main of PDI shows signiﬁcant sequence identity to Trx which
has the characteristic a/b fold with the structure of babababba
[19,20]. Fig. 4 shows the result for the homology modeling of
PDI’s a domain and the ﬁrst domain of Hcc-2 with the
WCXXC active-site motif highlighted in yellow. All the three
domains of Hcc-2 contain the active site with the sequence mo-
tif of CGHC which had been shown to be involved directly in
thiol–disulﬁde exchange reactions [17]. It is interesting to noteFig. 3. Predicted amino acid sequences of Hcc-2. Boxed peptides are the sign
motif, KDEL, located at the C-terminal of the protein, is in bold.that Hcc-2 is a novel protein possessing three a domains, which
is diﬀerent from all the earlier known PDI-related proteins
[19,21,22].
3.3. Cloning of human Hcc-2 cDNA
We used degenerate oligonucleotide primers to clone the
Hcc-2 gene from ﬁrst strand cDNA derived from poorly-diﬀer-
entiated HCC tissues. RACE was performed to obtain infor-
mation on the 5 0 and 3 0 untranslated regions of the gene.
The subsequent PCR products were sequenced and the fully
assembled DNA sequence were found to agree with the EST
assembled sequence of the protein. Fig. 5 shows the fully
assembled DNA sequence of Hcc-2 after conﬁrmation by
DNA sequencing. The cDNA contained an ORF of 1092 bp.
This ORF encodes a protein of 363 amino acids with a calcu-
lated molecular mass of 40.71 kDa. The amino acid sequence
of the encoded protein agrees with the predicted sequenceature peptide for Trx (CXXC) deﬁned by Interpro. The ER retention
Fig. 4. Homology modeling of the overlapping regions of Hcc-2 (aa 1–125) and the PDB structure of human protein disulﬁde isomerase (1 MEK).
The Hcc-2 structure is in blue and the 1 MEK structure is in red, while Cys20 and Cys23 in the Trx active site are in yellow.
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accession number AJ440721. We used this information to de-
sign primers spanning the putative ORF of the protein and
cloned the ORF. PCR experiments generated a single 1 kb
band on agarose gel electrophoresis (results not shown).
PCR product was cloned into TOPO vectors and numerous
positive clones were sequenced. This ORF was used for expres-
sion of Hcc-2 in baculovirus Sf9 cells.
3.4. Expression of recombinant Hcc-2
To conﬁrm the identity of this protein as well as the pre-
dicted Trx-like activity associated with the CGHC motifs, we
expressed Hcc-2 in baculovirus as a HIS-tagged protein. The
full length Hcc-2 protein has a KDEL motif for ER retention
at the C-terminus, hence we tagged a short HIS tag to the N-
terminus. The puriﬁed protein ran as a single band and mi-
grated at the range of 43–56 kDa on SDS–PAGE, higher than
the predicted molecular mass of 40 kDa (Fig. 6). Edman N-ter-
minal sequencing conﬁrmed the ﬁrst 19 amino acids as
MFTHGIQSAAHFVMFFAPW, exactly as predicted. This
conﬁrmed that we had isolated and cloned the Hcc-2 gene
and expressed its product.
3.5. Reductase activity of Hcc-2
Hcc-2 was identiﬁed as a putative Trx protein because of the
presence of the active site sequence CGHC. This protein is un-
ique in that it has three such domains (Fig. 3). In order to
determine if indeed these domains confer a Trx-like reducing
activity, we performed an insulin disulﬁde reduction assay
[11] using recombinant Hcc-2 which we expressed and puriﬁed
as described earlier. The negative control, which is DTT and
insulin did not exhibit any change in absorbance, indicating
no activity. With the positive control, which is puriﬁed recom-
binant E.coli Trx, a rapid increase in turbidity was observed.
Most importantly, the puriﬁed HIS-tagged Hcc-2 also exhib-
ited an increase in turbidity indicating that this protein does
have Trx-like reducing activity (Fig. 7). It is also apparent thatit is a poorer reductase compared to E. coli thioredoxin. This is
probably due to the diﬀerence in redox potentials as a result of
the diﬀerence in the nature of the two intervening residues of
the reactive CXXC sequence [19].
3.6. Localization of Hcc-2
Sequence analysis revealed a KDEL motif at the C-termi-
nus of Hcc-2. This KDEL motif is known to signal the
retention of proteins in the ER [23]. The presence of this
motif in Hcc-2 indicates that it might be localized to the
cytoplasm/ER. To conﬁrm this, we constructed vectors for
expression of Hcc-2 in mammalian cells. To facilitate single
cell cloning of positive transfectants and subsequent
localization of Hcc-2, a GFP was tagged to the N-terminus
of Hcc-2. The expression of the GFP-Hcc-2 gene is under
the control of the constitutive cytomegalovirus promoter.
Control plasmid expressing only GFP was also made.
CHO-K1 cell line was transfected with the constructs.
Positive ﬂuorescing cells were examined under microscope.
Control cells show ﬂuorescence throughout the cells
(Fig. 8A), while green ﬂuorescence in GFP-Hcc-2 cells were
enhanced in the cytoplasm but not in the nucleus
(Fig. 8B). This observation is consistent with the Hcc-2 pro-
tein being retained in the cytoplasm due to the KDEL signal.
3.7. Tissue distribution of Hcc-2 mRNA
We used qRTPCR to study the distribution of the Hcc-2
transcript in human tissues and cultured human cell lines.
We designed real-time PCR primers toHcc-2. The primers cor-
responded to 468–487 bp and 595–614 bp of Hcc-2 (Fig. 5),
respectively. Speciﬁcity of primer pair used was checked by se-
quence alignments and by analysis of dissociation curves
generated by the real time analysis. Human multiple tissue
cDNAs were used as templates. Fig. 9 shows the transcript
level of Hcc-2 in the diﬀerent tissues. Hcc-2 is ubiquitously
expressed in all 16 tissue types. High expression was detected
in the pancreas.
Fig. 5. Nucleic acid base sequence (and corresponding translation protein sequence) of Hcc-2. The sequence of cDNA clone Hcc-2 (GenBank
accession no. AJ440721) is shown. Nucleic acids in the open reading frame (ORF) and the noncoding regions are presented in uppercase and
italicised letters. The thioredoxin (CGHC) domains are bold and underlined.
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normal and HCC tissues
To determine the Hcc-2 mRNA expression level in normal
liver tissues as compared to HCC tissues, we perform RT-
PCR on the total RNA generated from normal human liver
and HCC tissues. A primer pair that generates a 751bp prod-
uct from the Hcc-2 gene was designed. Primers targeting b-ac-
tin (Actb-F and Actb-R) was used as loading control. As
Fig. 10 shows, the PCR product for Hcc-2, from HCC tissues
is more than that from normal tissues indicating a higher levelof Hcc-2 mRNA in the HCC tissues. An equal amount of
cDNA had been used for both samples as shown by the load-
ing control, actin. This result validates the protein expression
pattern shown by proteomic analysis.4. Discussion
In this work, we used an integrated approach of proteomics,
bioinformatics and genomics to clone and characterize a novel
Fig. 6. SDS–PAGE of recombinant Hcc-2 expressed in baculovirus
infected Sf9 insect cells. Hcc-2 was cloned into a baculovirus protein
expression system vector and expressed in Sf9 insect cells. Cells were
harvested at 72 h , lysed and the protein was batch puriﬁed on Talon
cobalt resins and analysed on a 12% SDS–polyacrylamide gel. The
recombinant protein exhibited a molecular weight of between 43 and
56 kDa, higher than the predicted size of 40.71 kDa. (M) Broad range
molecular weight marker (Biorad). (1) rHCC-2 bound to Talon resin,
after washing. (2) Puriﬁed rHcc-2 eluted from Talon resins.
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Fig. 7. Reductase activity of Hcc-2. Baculovirus expressed Hcc-2 and
E. coli TRX proteins were incubated with insulin and the reduction of
insulin disulﬁde bonds was measured by monitoring absorbance at
595 nm, every 2 min. d, 0.2 mg/ml E. coli TRX; m, 0.2 mg/ml rHcc-2;
¤, Blank control. The experiments were carried out in duplicates.
Fig. 8. Localization of Hcc-2 by confocal microscopy. Transfected
CHO-K1 cell ﬂuorescence images. Fluorescent images showing CHO-
K1 cells transfected with pEGFP-C2 (A) and pEGFP-170 (B). After
transient expression, cells were visualized with an Olympus IX70
inverted microscope. These data are representative of two separate
experiments. Images show that the control, which is GFP, is
distributed throughout the cell (A) whereas Hcc-2, which is tagged
to GFP is localized predominantly to cytoplasm (B). The Hcc-2 image
has been enlarged 400· to show the nuclei.
2222 P.M. Nissom et al. / FEBS Letters 580 (2006) 2216–2226Trx-related protein, Hcc-2. The Hcc-2 gene is ubiquitously ex-
pressed in normal human tissues (Fig. 9) and is upregulated in
poorly diﬀerentiated HCC tissues (Fig. 10). The protein con-
tains three redox active site and an ER retention signal se-
quence. We designate this protein, hepatocellular carcinoma
2 (Hcc-2), as it was the second upregulated protein identiﬁed
by proteomics based on our studies on hepatocellular carci-
noma [5,7]. Interestingly, the upregulation of Hcc-2 is charac-
teristic of the expression pattern of Trx-like proteins in some
cancers. For example, Trxs are known to be overexpressed in
a variety of human primary tumours compared to levels in
the corresponding normal tissues [24,25]. In patients with
HCC, the plasma and serum levels of Trx have been reported
to be elevated almost 2-fold and to decrease with surgical re-
moval of the tumour [26].
The Hcc-2 protein migrated consistently at 55 kDa in 2DE
despite that the protein has only 363 amino acids with a theo-retical molecular mass of 40.71 kDa (Fig. 1A). The recombi-
nant Hcc-2 protein has also migrated as greater than 43 kDa
in SDS–PAGE (Fig. 6). N-terminal amino acid sequencing
conﬁrmed that the band at 55 kDa contained the same N-ter-
minal sequence as the Hcc-2 protein. The deviation in migra-
tion may be due to the fact that Hcc-2 is a very hydrophilic
protein since it consists of only 34.7% hydrophobic amino
acids based on the Kyte–Doolittle plot and GRAVY (grand
average of hydropathy) index of 0.447. This high surface
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Fig. 9. Tissue distribution of Hcc-2 analysed by real time PCR. Relative transcript levels (RTL) of Hcc-2 expressed as mean RTL ± S.E.M. Values
were obtained from three technical replicates. The threshold cycle or the CT value is the cycle at which a signiﬁcant increase in the signal associated
with an exponential growth of PCR product during the log-linear phase is detected. The higher the initial amount of transcript, the sooner
accumulated product is detected in the PCR process, and the lower the CT value. The relative levels of Hcc-2 mRNA were determined by real time
PCR in the tissues indicated on the bottom of the ﬁgure using b-actin mRNA levels as a reference and normalization standard. The data shown were
obtained from three samples using the same preparations of tissue RNAs.
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to the protein in SDS–PAGE.
The predicted Hcc-2 protein (Genbank CAD29430.1) was
subsequently found to overlap with other human homologues
deposited in Genbank (GenBank accession no. BAC11526.1,
AAQ89009.1, Q8NBS9, CAH56286.1, AAR99514.1,
AAH01199.1, CAD39084.1, AAH52310.1). They all possess
the exact active site sequence (CGHC) as Hcc-2, but some of
them have diﬀerent lengths in the N-terminal segments
(Fig. 11). As a result, the last three proteins in the list above
(AAH01199.1, CAD39084.1, AAH52310.1) have only two
Trx-like domains, as compared with the other six proteins
(BAC11526.1, AAQ89009.1, Q8NBS9, CAH56286.1,
AAR99514.1 and Hcc-2) which have three Trx-like domains.
These homologues belonged to the TXNDC5 (thioredoxin
domain containing 5) gene family of proteins, which consistsFig. 10. Comparison of the mRNA expression level of Hcc-2 by RT-PCR ana
HCC tissues was used as template for PCR using primers to Hcc-2 and b-a
separated by agarose gel electrophoresis and photographed using a gel docu
while b-actin primers produce a 500 bp product. Lanes M, 1 kb marker (Pro
Hcc-2 – HCC tissue cDNA; 4, actin – normal liver tissue cDNA; 5, actin –of two variants, with variant 1 being the predominant tran-
script. Hcc-2 belongs to variant 1 but it is short of 69 amino
acids at the N-terminus. On the basis of the Kyte–Doolittle
hydropathy plot, there is a high possibility that a signal peptide
and a transmembrane region may exist at this additional 69
amino acids (result not shown). Hitherto, all these homologous
proteins do not have any biological functions assigned to them
yet.
As indicated above and in the results section earlier, one
interesting novel feature of Hcc-2 is that it contains three
Trx domains. These Trx domains have a similar active site se-
quence (CGHC) as the a domain of PDI (Fig. 4). It has been
well-established that proteins in the PDI superfamily consists
of 2a (represented by a and a 0) and 2b (represented by b and
b 0) domains, and a C-terminal acidic extension segment, and
that only the a and a 0 domains of PDI possess the Trx-likelysis. 3 ng of ﬁrst strand cDNA prepared from normal human liver and
ctin. PCR reaction was carried out over 30 cycles. The products were
mentation system (BioRad). Hcc-2 primers generate a 751 bp product
mega); 1, no template control; 2, Hcc-2 – normal liver tissue cDNA; 3,
HCC tissue cDNA.
Fig. 11. Clustalw output of Hcc-2 with the human variants of TXNDC5 deposited in Genbank. Hcc-2 (CAD29430.1) was aligned with human
variants of TXNDC5. The conserved active site is in bold. Identical amino acids between the three proteins are marked with asterisks. The numbers
next to the sequences represent NCBI Genbank accession number.
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was conﬁrmed by the insulin disulﬁde reducing assay (Fig. 8)
which detects the reduction of the two interchain disulﬁde
bonds of insulin. In a recent paper, Knoblach et al. [27] iden-
tiﬁed ERp46 as a new member of the thioredoxin family of
endoplasmic reticulum proteins. ERp46, having a sequence
homology of 77.5% with Hcc-2, and consisting of 417 amino
acids, also contained three CGHC domains. Functional stud-
ies using a complementation assay in the yeast S. cerevisiae
demonstrated that it had a PDI-like activity.
Besides Hcc-2 and ERp46, the other proteins known to-
date that have three CXXC domains are ERp72 and hPDIR
(human protein–disulﬁde isomerase-related) protein. How-ever, hPDIR protein has a domain structure of b–a–a 0–ao,
while ERp72’s domain structure is c–ao–a–b–b 0–a 0. The a do-
main of ERp72 is similar to PDI, i.e., it consists of an active
site sequence of CGHC. ERp72 is an abundant ER resident
protein and it catalyzes the reduction, oxidation and isomer-
ization of disulﬁde-bonded proteins in vitro [28]. It is interest-
ing to note that the isomerase activity of ERp72 is less than
PDI [28], considering that PDI has only two CGHC domains.
This suggests that ERp72 may have possible multifunctional
role other than those being involved in disulﬁde bond isom-
erization. For example, ERp72 did not exhibit peptide-
binding capacity [29], but in conjunction with BiP, they
co-precipitated over expressed human chorionic gonadotropin
Fig. 11 (continued)
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with the molecular chaperones, PDI, BiP and GRp94, it
has been shown to interact in vitro with denatured proteins
[31] and apolipoprotein B [32]. This was also observed
in vivo for thyroglobulin and thrombospondin [33]. In addi-
tion, ERp72 was shown to co-precipitate with laminin during
diﬀerentiation of mouse F9 teratocarcinoma cells [34]. On the
other hand, hPDIR protein has three diﬀerent a domains
with the following active site sequences: CSMC, CGHC,
CPHC, respectively. It has been shown recently that it has
isomerase and chaperone activities and that its expression is
stress-inducible [35]. Furthermore, mutation studies showed
that the three diﬀerent Trx domains of hPDIR contribute
to its isomerase activity with a rank order of CGHC >
CPHC > CSMC. However, interestingly, both its isomerase
and chaperone activities were found to be lower than those
of PDI [35].
In summary, we have isolated and partially characterized a
novel protein, Hcc-2, that was found to be upregulated in hu-
man hepatocellular carcinoma based on proteome analysis of
liver HCC tissues. In addition to its disulﬁde isomerase func-
tion, Hcc-2, similar to the other known proteins with three ac-
tive site CGHC domains (Fig. 11, ERp46, ERp72 and hPDIRprotein) may have other functions that are unknown at pres-
ent. For example it may act via complex formation in a man-
ner similar to ERp72. Thus Hcc-2 could be involved in ER
stress response by forming complexes with other molecular
chaperones. This will form the basis of our future studies on
this protein with the aim to unravel its role in HCC and tu-
mour development. This work demonstrates that an integrated
proteomics and genomics approach can be a very powerful
means of discovering potential diagnostic and therapeutic pro-
tein targets for cancer therapy.Acknowledgements: We thank Siow Qi Chang and Hong Guan Lim
for excellent support in cell culture experiments, Lu Zheng for MS
veriﬁcation, C-terminal and N-terminal sequencing, Ally Lau and
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